FTC Report Finds Pharmacy Benefit Managers Inflate Drug Prices

FTC report finds PBM power has “dire consequences”

The FTC's long-awaited report on pharmacy benefit managers is out, and makes uncomfortable reading for the pharma supply chain middlemen.

Pharmacy middlemen wreak havoc on the health care system

The Federal Trade Commission’s new report on prescription drug middlemen paints a stark picture. Not only for patients caught in the crosshairs of organizations’ pharmacy benefit managers but also independent pharmacists. To quote Federal Trade Commission Chair Lina Khan: “Pharmacy benefit managers can squeeze independent pharmacies that many Americans — especially those in rural communities

Alternative PBMs Arise to Compete With the 'Big Three'

Competitors say their per-member, per-month payment model is fairer to employers and insurers

Pharmacy middlemen face new allegations of skimming • Ohio Capital Journal

Mint Images/Getty Images.It was always the suspicion. When shadowy pharmacy middlemen started in 2019 to create yet another layer of middlemen, critics suspected they would be used to avoid transparency and skim even more money from the interstices of arcane — but wildly lucrative — drug transactions. Now evidence is accumulating that it might be happening. Two government investigations this year accused the giant health conglomerates that own t…

The FTC Wrongly Blames PBMs for High Drug Prices

The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.

FTC Blasts PBM Business Practices

An FTC report says pharmacy benefit managers have “enormous power” over prescription drug prices and drug access. Learn more from the new report.